Pursuing New Paradigms in Prostate Cancer

Welcome to OncLive On Air^™! I’m your host today, Caroline Seymour.

OncLive On Air^™ is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

At the meeting, faculty provided insight into treatment decisions in metastatic hormone-sensitive prostate cancer, the role of testing for somatic and germline mutations, practice-changing trials in the metastatic setting, and standards of care in the nonmetastatic castration-resistant setting.

First, we spoke with the chair of the meeting, Daniel P. Petrylak, MD, a professor of medicine and urology and coleader of Cancer Signaling Networks at Yale Cancer Center. Listen on to hear Petrylak discuss pivotal trials that have read out in HSPC and recommendations for treatment selection.

We were then joined by Leonard G. Gomella, MD, the Bernard W. Godwin, Jr, Professor of Prostate Cancer and chairman of the Department of Urology at Sidney Kimmel Medical College of Thomas Jefferson University, director of the Kimmel Cancer Center Network, and cochair of the 2019 Prostate Cancer Consensus Conference. Listen on to hear Gomella discuss the growing importance of genetic testing in prostate cancer.

Joseph Kim, MD, an associate professor of internal medicine at Yale School of Medicine, also stopped by to discuss pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

We closed out the night with Michael Hurwitz, MD, an associate professor of internal medicine at Yale Cancer Center. Listen on to hear Hurwitz discuss the role of second-generation androgen blockers in nonmetastatic CRPC, how these agents compare, and active areas of investigation.